Text tabled : A7-0165/2012

  Zbigniew Ziobro (EFD), in writing. – (PL) I welcome the McAvan report. Unfortunately, we have a serious problem in Europe over the safety of pharmaceuticals and the way their use is monitored. I hope that with today’s report, we will take the first of the many steps which have to be taken to improve safety and that, as a consequence, we will make a real improvement to the medical treatment Europeans receive and to their health. The case in 2011 of the medicine Mediator represents only a fraction of the chaos which reigns in the pharmaceuticals market. For example, I would like to call renewed attention to the problems with stents, which continued to be authorised for use in many of the EU’s Member States, despite the fact that in the US, from where they were imported, authorisation for their use had been withdrawn. The need to promote citizens’ welfare means we have to prevent such situations from arising.